lifestyle.newsblaze.com

Author: SpyGlass Pharma, Inc.

SpyGlass Pharma Announces Positive Topline 12-Month Phase 1/2 Trial Results for Its Innovative BIM-IOL System

March 9, 2026
SpyGlass Pharma to Participate in the Jefferies Biotech on the Beach Summit

March 4, 2026
SpyGlass Pharma Announces Closing of Initial Public Offering and Exercise in Full of the Underwriters’ Option to Purchase Additional Shares

February 12, 2026
SpyGlass Pharma Announces Pricing of Initial Public Offering

February 11, 2026
SpyGlass Pharma Announces First Patients Randomized in SGP-005 and SGP-006, Two Registrational Phase III Clinical Trials of Its Novel BIM-IOL System

January 20, 2026